Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Capricor Therapeutics (CAPR) over the last 12 years, with Q3 2025 value amounting to $78.2 million.

  • Capricor Therapeutics' Change in Acquisitions & Divestments rose 25766.16% to $78.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.1 million, marking a year-over-year increase of 12135.7%. This contributed to the annual value of $93.8 million for FY2024, which is 1032.63% down from last year.
  • Capricor Therapeutics' Change in Acquisitions & Divestments amounted to $78.2 million in Q3 2025, which was up 25766.16% from $76.0 million recorded in Q2 2025.
  • In the past 5 years, Capricor Therapeutics' Change in Acquisitions & Divestments registered a high of $78.2 million during Q3 2025, and its lowest value of $14.0 million during Q2 2022.
  • For the 4-year period, Capricor Therapeutics' Change in Acquisitions & Divestments averaged around $34.2 million, with its median value being $29.1 million (2022).
  • As far as peak fluctuations go, Capricor Therapeutics' Change in Acquisitions & Divestments tumbled by 4885.9% in 2023, and later skyrocketed by 25766.16% in 2025.
  • Quarter analysis of 4 years shows Capricor Therapeutics' Change in Acquisitions & Divestments stood at $38.4 million in 2022, then crashed by 48.86% to $19.6 million in 2023, then dropped by 14.89% to $16.7 million in 2024, then soared by 367.64% to $78.2 million in 2025.
  • Its last three reported values are $78.2 million in Q3 2025, $76.0 million for Q2 2025, and $43.2 million during Q1 2025.